You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR REMIMAZOLAM BESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Remimazolam Besylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04790734 ↗ Remimazolam Besylate in Mechanically Ventilated ICU Patients Not yet recruiting Wuhan Union Hospital, China Phase 3 2021-03-01 The purpose of this study is to evaluate the efficacy and safety of remimazolam compared to propofol for sedation in mechanically ventilated ICU patients.
NCT04947345 ↗ The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients Not yet recruiting Yichang Humanwell Pharmaceutical Co.,Ltd Phase 3 2021-09-01 This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.
NCT04947345 ↗ The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients Not yet recruiting Peking Union Medical College Hospital Phase 3 2021-09-01 This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.
NCT05103696 ↗ A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients Not yet recruiting Peking University People's Hospital N/A 2021-11-01 Studies have shown that etomidate combined with propofol in gastroscopy has high safety and lower incidence of hypoxia and hypotension, suggesting the advantages of etomidate combined with propofol in elderly patients. Remimazolam Besylate is a 1.1 class new drug that acts on GABA receptors and is metabolized by plasma esterase with fast metabolism time, only 1/7 of midazolam, which may be more suitable for elderly patients. Therefore, this study intends to explore the safety and effectiveness of two sedation schemes in gastroenteroscopy for elderly patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Remimazolam Besylate

Condition Name

Condition Name for Remimazolam Besylate
Intervention Trials
Remimazolam 3
Remimazolam Besylate 3
Sedation 3
General Anesthesia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Remimazolam Besylate
Intervention Trials
Critical Illness 4
Obesity 1
Atrial Fibrillation 1
Vomiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Remimazolam Besylate

Trials by Country

Trials by Country for Remimazolam Besylate
Location Trials
China 12
Korea, Republic of 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Remimazolam Besylate

Clinical Trial Phase

Clinical Trial Phase for Remimazolam Besylate
Clinical Trial Phase Trials
Phase 4 8
Phase 3 4
Phase 2 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Remimazolam Besylate
Clinical Trial Phase Trials
Not yet recruiting 18
Recruiting 10
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Remimazolam Besylate

Sponsor Name

Sponsor Name for Remimazolam Besylate
Sponsor Trials
Wuhan Union Hospital, China 7
Seoul National University Hospital 4
Yichang Humanwell Pharmaceutical Co., Ltd., China 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Remimazolam Besylate
Sponsor Trials
Other 31
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.